Dow Hits Record as Wall Street Rallies on Iran De-escalation Hopes

Stocks Rally as Trump Holds Off on Iran Strikes

US stocks closed sharply higher on Monday, with the Dow Jones Industrial Average setting a new record, as investors bet that the risk of a wider Middle East conflict was receding. President Donald Trump said on Truth Social that he had decided against carrying out planned large-scale strikes on Iran for now, citing a request from Tehran and other Middle Eastern countries, and suggested an agreement related to the Strait of Hormuz could be reached very soon. He added that the United States could resume strikes at any time if necessary.

The Dow rose 1.32% to 53,178.41 points, Standard & Poor's 500 climbed 1.48% to 7,600.5, and the Nasdaq Composite advanced 2.13% to 25,913.9. Oil prices fell sharply, pushing Chevron and Exxon Mobil down 1.9% and 0.2% respectively. Amazon jumped 4.6%, lifting its market value above $3 trillion.

Merger news also drove single-stock moves. Lantheus climbed 1.6% after Curium's US unit agreed to buy the pharmaceutical company for up to $8 billion, or $102.5 per share plus up to $12 in conditional payments. KKR agreed to acquire medical-device maker Integer Holdings for about $5.7 billion, sending Integer up 2.7%. Bristol Myers Squibb added 0.2% on reports it is exploring a tie-up with AstraZeneca that would create a drugmaker with a combined market capitalisation of nearly $400 billion. Tyson Foods rose 2.9% after its fiscal third-quarter net profit tripled on roughly flat revenue, while Marriott International dropped 7% after its second-quarter revenue rose 5%, below expectations.

De-escalation, Deal Flow and Diverging Earnings Behind the Record Close

De-escalation, or an Easily Reversed Pause?

The market's reaction is understandable but fragile. Verified facts: Trump said he postponed the strikes to try peaceful means first, expects a Hormuz-related agreement soon, and warned that the US could strike again at any moment. Interpretation: investors are pricing a lower probability of near-term conflict and the accompanying oil-supply risk, rather than a durable political settlement. Falling crude was the cleanest expression of that shift — and it explains the simultaneous decline in Chevron and Exxon, whose revenues are directly exposed to oil prices.

B. Riley Wealth strategist Art Hogan framed the session's logic: traders wake up and first check oil and the US 10-year Treasury yield. When both are falling, equities tend to feel safe. That remains the monitoring framework going forward.

Healthcare M&A Is Back in Focus

Two transactions announced in the session — Curium's up-to-$8 billion purchase of Lantheus and KKR's roughly $5.7 billion acquisition of Integer Holdings — show sustained buyer appetite for healthcare and medical-technology assets at full valuations. The $102.5-per-share cash price plus conditional upside for Lantheus implies acquirers are still willing to pay premiums for strategic fit.

Bigger still is the reported, but unconfirmed, exploration of a merger between Bristol Myers Squibb and AstraZeneca. A combined company with a near-$400 billion market value would sit among the largest drugmakers globally, reshaping competitive dynamics. Until confirmed, it should be treated as a rumour, but the mere report moved Bristol Myers shares and signals where boardrooms are looking.

Earnings Distinguish the Winners From the Laggards

Monday's tape was not uniformly about geopolitics. Tyson Foods gained 2.9% after tripling fiscal third-quarter net profit even with roughly flat revenue — evidence that margins, not growth, are currently driving sentiment in parts of the food sector. Amazon's 4.6% jump, which pushed its market value past $3 trillion, keeps big technology as the main engine of index gains.

Marriott cut in the other direction, falling 7% when 5% second-quarter revenue growth missed expectations — a reminder that lodging demand is being priced more cautiously. The takeaway from the session is that index records can mask sharp fundamental divergence underneath.

Signals Investors Should Track After Monday's Rally

Monday's record close is a headline-driven rally, not a fundamental repricing. For investors and market professionals, the day offers several concrete focal points rather than a clear directional signal.

• Watch Trump's social-media statements and Iranian responses: the president explicitly reserved the right to resume strikes, so the same channel that triggered the rally could reverse it within hours.
• Treat oil prices and the 10-year US Treasury yield as the market's first risk screen, as B. Riley Wealth's Art Hogan put it. A renewed spike in either would likely be met with equity selling.
• For energy-exposed investors, Chevron's 1.9% and Exxon's 0.2% declines show the geopolitical premium is deflating; the promised Hormuz talks are the key variable to track.
• In healthcare, treat the Bristol Myers Squibb–AstraZeneca report as unconfirmed and watch for regulatory filings; the Curium–Lantheus and KKR–Integer deals are concrete reference points for sector valuations.
• Earnings divergence matters: Tyson's margin-driven gain and Marriott's demand-driven drop show single-name risk is elevated even as broad indices hit records.